Evaluation of CLL: Transitioning from a SNP-array CGH platform to an NGS-based CNV + SNV approach

Dr Fortin will talk about transitioning from microarray to the SureSeq™ CLL + CNV NGS panel, and how the SureSeq CLL + CNV NGS Panel delivers a comprehensive genomic profile for each CLL sample using a single workflow, including trisomy 12, 11q, 13q and 17p deletions.
Disclaimer: This presentation is intended for educational purposes only and does not replace independent professional judgment. Statements of fact and opinions expressed are those of the presenters individually and, unless expressly stated to the contrary, are not the opinion or position of the Oxford Gene Technology Group (OGT). OGT does not endorse or approve, and assumes no responsibility for, the content, accuracy or completeness of the information presented.